Menezes Ravi J, Swede Helen, Niles Robert, Moysich Kirsten B
Department of Epidemiology, Roswell Park Cancer Institute, A-316 Carlton House, Buffalo, NY 14263, USA.
Cancer Causes Control. 2006 Apr;17(3):251-6. doi: 10.1007/s10552-005-0450-z.
It has been hypothesized that aspirin and other nonsteroidal anti-inflammatory drugs can decrease the risk of developing prostate and other cancers, although observational studies have not been very conclusive. The current study examined the effects of regular aspirin use on prostate cancer risk in 1,029 patients with primary, incident cancer of the prostate and 1,029 hospital controls frequency-matched to cases by 5-year age group and period of questionnaire completion. Patients who reported use of aspirin for at least once a week for at least 6 months were classified as regular users, with others classified as non-users. Results indicate that regular aspirin use may not be associated with decreased prostate cancer risk [odds ratio (OR) 1.05, 95% confidence interval (CI) 0.89-1.25], frequency of use (OR for at least seven/week 0.91, 95% CI 0.73-1.13), duration of use (OR for at least 10 years of use 1.17 95% CI 0.93-1.46) or tablet years (defined as tablets per day x years of use). A similar lack of association was observed when analyses were performed examining stage of the cancer. These data suggest that aspirin use may not be associated with reduced risk of prostate cancer.
有假设认为，阿司匹林和其他非甾体抗炎药可以降低患前列腺癌及其他癌症的风险，尽管观察性研究的结论并不十分确凿。本研究调查了1029例原发性前列腺癌患者和1029例医院对照者（按5岁年龄组和问卷完成时间与病例进行频率匹配）中规律服用阿司匹林对前列腺癌风险的影响。报告每周至少服用一次阿司匹林且持续至少6个月的患者被归类为规律使用者，其他患者则归类为非使用者。结果表明，规律服用阿司匹林可能与前列腺癌风险降低无关[比值比（OR）为1.05，95%置信区间（CI）为0.89 - 1.25]，服用频率（每周至少七次的OR为0.91，95%CI为0.73 - 1.13）、服用持续时间（至少服用10年的OR为1.17，95%CI为0.93 - 1.46）或片剂年数（定义为每日服用片数×服用年数）均无关联。在分析癌症分期时也观察到了类似的无关联情况。这些数据表明，服用阿司匹林可能与前列腺癌风险降低无关。
